INVESTIGATION OF A THIRD GENERATION ECHO-CONTRAST AGENT

Information

  • Research Project
  • 6054047
  • ApplicationId
    6054047
  • Core Project Number
    R41RR014886
  • Full Project Number
    1R41RR014886-01
  • Serial Number
    14886
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/15/2000 - 24 years ago
  • Project End Date
    6/14/2001 - 23 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    6/15/2000 - 24 years ago
  • Budget End Date
    6/14/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/13/2000 - 24 years ago

INVESTIGATION OF A THIRD GENERATION ECHO-CONTRAST AGENT

Recently, collaborations between medical industries and academia have directly benefitted the development of ultrasound contrast agents (UCAs). First generation UCAs consisted of stabilized air-filtered microbubbles. A lack of persistence, led to second generation UCA's, consisting of microbubbles containing high molecular weight gases. Third generation agents are now being pursued. These agents provide, in addition to good sensitivity and long persistence, Selective Fragility, useful in imaging and in drug delivery. The physics of Selective Fragility is complex, and not well understood. The applicants propose to study these microbubbles destruction mechanisms by constructing custom microbubbles, and evaluating them using improved measurement tools and theoretical models. Point Biomedical Corp. will supply custom microbubbles (biSphere(tm)) to the Applied Physics Laboratory (APL) along with acoustic scatter data and high temporal resolution microscope images. The response of these microbubbles to pulsed ultrasound will be characterized at APL by adapting a unique light scattering system that has been used to study cavitation dynamics. This system is capable of real-time direct measurements of a bubble's radial oscillation. "Clumps" of UCAs will also be, measured to access the backscatter amplitude and cavitation thresholds. Successful completion of this project will lead to significant innovations in both diagnostic and therapeutic ultrasound. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R41
  • Administering IC
    RR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    126958
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    371
  • Ed Inst. Type
  • Funding ICs
    NCRR:126958\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    POINT BIOMEDICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN CARLOS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940703312
  • Organization District
    UNITED STATES